These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17501862)

  • 1. Patient information regarding subcutaneous self-administration of dihydroergotamine (DHE).
    Rothrock JF
    Headache; 2007 May; 47(5):740. PubMed ID: 17501862
    [No Abstract]   [Full Text] [Related]  

  • 2. Dosing and administration of ergotamine tartrate and dihydroergotamine.
    Mathew NT
    Headache; 1997; 37 Suppl 1():S26-32. PubMed ID: 9009471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of subcutaneous dihydroergotamine by home injection for migraine.
    Becker WJ; Riess CM; Hoag J
    Headache; 1996 Mar; 36(3):144-8. PubMed ID: 8984085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
    Lipton RB
    Headache; 1997; 37 Suppl 1():S33-41. PubMed ID: 9009472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.
    Silberstein SD; Young WB; Hopkins MM; Gebeline-Myers C; Bradley KC
    Headache; 2007 Jun; 47(6):878-85. PubMed ID: 17578539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydroergotamine nasal spray in the treatment of acute migraine.
    Treves TA; Kuritzky A; Hering R; Korczyn AD
    Headache; 1998 Sep; 38(8):614-7. PubMed ID: 11398305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of acute attacks of migraine by dihydergot: nasal aerosols].
    Solov'eva AD; Filatova EG; Veĭn AM
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(2):21-4. PubMed ID: 10081130
    [No Abstract]   [Full Text] [Related]  

  • 8. Patient information regarding subcutaneous self-administration of sumatriptan (imitrex).
    Rothrock JF
    Headache; 2007 Apr; 47(4):639. PubMed ID: 17445120
    [No Abstract]   [Full Text] [Related]  

  • 9. DHE in the pharmacotherapy of migraine: potential for a larger role.
    Saper JR; Silberstein S; Dodick D; Rapoport A
    Headache; 2006 Nov; 46 Suppl 4():S212-20. PubMed ID: 17078853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Migraine: dihydroergotamine nasal spray--an alternative].
    Beubler E
    Wien Med Wochenschr; 1995; 145(14):326-31. PubMed ID: 7483646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sumatriptin vs dihydroergotamine: patient preference.
    Tfelt-Hansen P; Steiner TJ
    Int J Clin Pract; 2001 Mar; 55(2):151. PubMed ID: 11321860
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache.
    Swidan SZ; Lake AE; Saper JR
    Curr Pain Headache Rep; 2005 Feb; 9(1):65-70. PubMed ID: 15625028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives.
    Young WB
    Headache; 1997; 37 Suppl 1():S42-5. PubMed ID: 9009473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ergot pharmacology and alternative delivery systems for ergotamine derivatives.
    Goldstein J
    Neurology; 1992 Mar; 42(3 Suppl 2):45-6. PubMed ID: 1557192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacology of ergotamine and dihydroergotamine.
    Silberstein SD
    Headache; 1997; 37 Suppl 1():S15-25. PubMed ID: 9009470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible iatrogenic bilateral cerebral ischemic infarcts in a woman with vasculitis.
    Farooq MU; Naravetla B; Bhatt A; Masih A; Macfalda B; Kassab MY
    J Headache Pain; 2008 Jun; 9(3):189-90. PubMed ID: 18418549
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler.
    Shrewsbury SB; Cook RO; Taylor G; Edwards C; Ramadan NM
    Headache; 2008 Mar; 48(3):355-67. PubMed ID: 18179563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous dihydroergotamine vs subcutaneous sumatriptan.
    Catarci T; Cerbo R
    Arch Neurol; 1996 Dec; 53(12):1215-6. PubMed ID: 8970446
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics.
    Shrewsbury SB; Kori SH; Miller SD; Pedinoff A; Weinstein S
    Curr Med Res Opin; 2008 Jul; 24(7):1977-85. PubMed ID: 18534051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine.
    Saper JR; Silberstein S
    Headache; 2006 Nov; 46 Suppl 4():S171-81. PubMed ID: 17078849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.